LSTA
Lisata Therapeutics, Inc. Common Stock
stockNASDAQ
caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.04 | 2026-10-20 | -1.92% | 4.541 |
| 1M | 1.50 | 2026-09-28 | -32.00% | 0.499 |
| 3M | 1.44 | 2026-07-27 | -29.17% | 1.616 |
| 6M | 3.12 | 2026-04-27 | -67.31% | -0.110 |
| 1Y | 2.80 | 2025-10-27 | -63.57% | 0.759 |
| 2Y | 2.88 | 2024-10-28 | -64.58% | — |
| 5Y | 5.00 | 2022-09-16 | -79.60% | 0.308 |
Lisata Therapeutics, Inc. Common Stock (NASDAQ:LSTA) stock price today is $1.02, and today's volume is 40,276. LSTA is down 3.774% today. The 30 day average volume is 212,364. LSTA market cap is $11.02M with 10.80M shares outstanding.